Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dementia with Lewy bodies.

Ian McKeith1, Jacobo Mintzer, Dag Aarsland

  • 1Institute for Ageing and Health, University of Newcastle, Newcastle upon Tyne, UK. i.g.mckeith@ncl.ac.uk

The Lancet. Neurology
|December 25, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.

Nature communications·2026
Same author

Social vulnerability shapes deep clinical phenotypes and brain health in aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Midlife dementia risk and later dementia-related fear and avoidance: evidence from a prospective cohort study.

Aging & mental health·2026
Same author

Genetic risk of Alzheimer's disease is associated with loss of brain network segregation in midlife.

Communications biology·2026
Same author

The relative contribution of modifiable and non-modifiable factors for determining cognition in mid-life individuals at risk for late-life Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Neural embedding of frailty in cognitively unimpaired aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia. Early identification and specific treatments, like cholinesterase inhibitors, can significantly improve symptoms and patient outcomes.

Area of Science:

  • Neuroscience
  • Geriatrics
  • Neuropathology

Background:

  • Dementia with Lewy bodies (DLB) is the second leading cause of neurodegenerative dementia in the elderly.
  • DLB shares clinical and pathological features with Parkinson's disease dementia, involving alpha-synuclein aggregation.
  • Accurate diagnosis is crucial due to unique patient symptoms and functional impairments.

Purpose of the Study:

  • To review the current scientific understanding of Dementia with Lewy bodies (DLB).
  • To highlight the importance of accurate DLB patient identification.
  • To discuss current and potential therapeutic strategies for DLB.

Main Methods:

  • Literature review of scientific knowledge on DLB.
  • Analysis of clinical and pathological characteristics.

Related Experiment Videos

  • Evaluation of treatment efficacy and safety.

    • Main Results:

    • DLB patients exhibit distinct symptoms and disabilities compared to other dementias.
    • Severe neuroleptic sensitivity reactions increase DLB patient morbidity and mortality.
    • Cholinesterase inhibitors effectively manage cognitive and neuropsychiatric symptoms in most DLB patients.

    Conclusions:

    • Clear management guidelines for DLB are urgently needed.
    • DLB is increasingly recognized as a treatable neurodegenerative disorder.
    • Further research and clinical guidance can optimize DLB patient care.